Most research teams think the hard part of IRB compliance is catching every event. The harder part, the one that actually generates audit findings, is knowing which events to skip. FDA’s Bioresearch Monitoring program flagged IRB reporting procedure deficiencies in both fiscal year 2022 and 2023 inspections, and the pattern is consistent: sites over-report minor deviations that add no oversight value while missing the nuanced signals that genuinely change a study’s risk profile. A new reportable events checklist from Advarra addresses that gap directly, with a checkpoint-by-checkpoint decision framework that forces the right question at each stage rather than defaulting to “when in doubt, submit.”
The framework runs nine checkpoints, but the logic pivots on three. Checkpoints two through four do the heaviest work: was the event unexpected relative to the protocol or investigator brochure, is there a reasonable possibility it’s related to study participation, and does it suggest a new or heightened risk to participants? All three have to point toward yes before an event clears the unanticipated problem threshold. Checkpoint five adds a layer specific to drug and biologic studies: a serious adverse event involving death, hospitalization, or a life-threatening condition still has to clear those same unexpected-related-increased-risk criteria before it becomes a prompt IRB report. Seriousness alone is not enough, and sites that treat every SAE as an automatic submission are doing the equivalent of filing noise.
Device studies get their own checkpoint around unanticipated adverse device effects, where the analysis also triggers a practical question: does the event require urgent corrective action, device modification, or participant notification before the next scheduled review? Protocol deviations follow a similar principle. A minor administrative error that touched no one’s safety and left data integrity intact generally does not warrant a prompt report; a deviation implemented to eliminate an immediate hazard, or one that compromised informed consent, does, along with a documented corrective and preventive action plan. The checklist also covers new safety information (checkpoint eight) and immediate protective actions (checkpoint nine), both of which can require consent-form revisions or study suspension before an IRB formally reviews the event.
Advarra’s IRB services support more than 60% of clinical trials in North America, which means the reporting habits this checklist is designed to correct play out across a substantial share of active studies. The metric worth watching at the site level is simpler than any compliance audit: the ratio of submissions that result in IRB action versus those that are acknowledged and closed with no change. A high proportion of the latter suggests over-reporting, and over-reporting has a cost, both in staff time and in the attention it draws away from events that actually matter.
Source link: https://www.advarra.com/blog/irb-reportable-events-checklist/
Moe Alsumidaie, MBA, MSF, is founder and Chief Editor of Vanguard Publications, which publishes Clinical Trial Vanguard, Pharma Vanguard and BullScope, and Head of Research at CliniBiz. He has two decades in clinical trial operations and data science, with earlier roles at Genentech, Abbott Vascular and Stanford University Medical Center, and is a guest lecturer in clinical trial sciences at Rutgers University.
